作者：汪俊逸，徐子辉，高凌

单位：

430060 湖北省武汉市，武汉大学人民医院内分泌科通信作者：高凌，E-mail：linggao@whu.edu.cn

Units：

Department of Neonatology, Renmin Hospital of Wuhan University, Wuhan 430060, ChinaCorresponding author: GAO Ling, E-mail: linggao@whu.edu.cn

关键词：

糖尿病; 糖尿病神经病变; 钠-葡萄糖协同转运体2; 交感神经系统;

Keywords：

Diabetes mellitus; Diabetic neuropathies; Sodium-glucose cotransporter 2; Sympathetic nervous system

CLC：

DOI：

10.12114/j.issn.1008-5971.2022.00.005

Funds：

摘要：

钠-葡萄糖协同转运体2(SGLT2)抑制剂虽然已广泛应用于糖尿病、心脏病、肾脏病等疾病的治疗,但其具体的作用机制并不完全明确。本文以SGLT2抑制剂作用于自主神经系统的病理生理机制为背景,从心血管自主神经角度对相关基础研究和临床研究进行综述,发现SGLT2抑制剂可通过调节自主神经功能改善糖尿病患者心血管疾病预后,而这种作用机制可能是通过中枢神经系统介导的。

Abstract：

【Abstract】 Although sodium glucose cotransporter 2 (SGLT2) inhibitors have been widely used in diabetes, cardiology andnephrology, but the specific mechanisms are still poorly understood. Based on the pathophysiological mechanism of SGLT2 inhibitorsacting on autonomic nervous system, this review summarizes the relevant basic research and clinical research from the perspectiveof cardiovascular autonomic nervous, and finds that SGLT2 inhibitors improves the prognosis of cardiovascular disease in diabeticpatients by regulating the function of autonomic nervous, and this mechanism may be mediated by central nervous system.

ReferenceList：